Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2015

Conditions
Acute Respiratory Distress Syndrome
Interventions
BIOLOGICAL

Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells

Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.

Trial Locations (4)

15213

University of Pittsburgh Medical Center, Pittsburgh

94143

University of California San Francisco Medical Center, San Francisco

94305

Stanford University Medical Center, Stanford

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Massachusetts General Hospital

OTHER

collaborator

Stanford University

OTHER

collaborator

University of Pittsburgh

OTHER

collaborator

University of Minnesota

OTHER

lead

Michael A. Matthay

OTHER

NCT01775774 - Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome | Biotech Hunter | Biotech Hunter